Supernus to Participate in Annual Piper Sandler Healthcare Conference
November 18, 2020 22:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at Two November Investor Conferences
November 11, 2020 23:14 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Provides Regulatory Updates for SPN-812 and SPN-830
November 09, 2020 18:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Third Quarter 2020 Financial Results
November 03, 2020 16:30 ET
|
Supernus Pharmaceuticals, Inc.
Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 millionQ3 2020 operating earnings of $56.1 millionOn track to initiate commercial...
Supernus to Host Third Quarter 2020 Financial Results Conference Call
October 27, 2020 17:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer
October 05, 2020 16:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two Treatments
September 14, 2020 08:15 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
September 09, 2020 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at the Wells Fargo Virtual Health Care Conference
September 02, 2020 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Second Quarter 2020 Financial Results
August 18, 2020 18:06 ET
|
Supernus Pharmaceuticals, Inc.
Total revenue of $126.7 million, including net product sales of $89.7 million for Trokendi XR®, $23.7 million for Oxtellar XR®, and $10.6 million for the acquired Parkinson’s disease (PD)...